Serum levels of omentin and visfatin in patients with metabolic syndrome

Metabolic Syndrome (MetS) is a global health concern characterised by cardiometabolic risk factors, dysregulated adipokine signalling and inflammation. The study aimed to assess the serum levels of omentin and visfatin in patients with metabolic syndrome. The 84-subject hospital-based case-control study included 18–55 years, both genders. Anthropometry, medical history, fasting plasma glucose (FPG), lipid profile, and HOMA-IR were collected. Insulin, omentin, and visfatin were measured using ELISA. Omentin and visfatin levels significantly differed between groups (<i>p</i> &lt; 0.05). The median omentin levels were 50.74 and 45.25; visfatin levels were 0.064 and 0.001, respectively. Omentin correlated with waist circumference, blood pressure, and FPG in controls, while visfatin correlated with HDL and BMI among cases (<i>p</i> &lt; 0.05). Omentin and visfatin were elevated in cases. However, no significant correlation between omentin and visfatin with lipid parameters could be established. Omentin and visfatin levels varied significantly between metabolic syndrome and controls; their correlation with MetS criteria was not significant.